These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged. Levy MS Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582 [TBL] [Abstract][Full Text] [Related]
43. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Panattoni LE J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873 [TBL] [Abstract][Full Text] [Related]
44. A Method for Approximating Future Entry of Generic Drugs. Beall RF; Darrow JJ; Kesselheim AS Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781 [TBL] [Abstract][Full Text] [Related]
45. Strategies That Delay Market Entry of Generic Drugs. Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217 [TBL] [Abstract][Full Text] [Related]
46. Biotech and pharma face more costly clinical trials. Brower V Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762 [No Abstract] [Full Text] [Related]
47. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right? Downing NS JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529 [No Abstract] [Full Text] [Related]
48. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry. Brockmeier MS Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564 [No Abstract] [Full Text] [Related]
49. Global Follow-On Biologics--IBC's Fifth Annual Conference. 10-11 December 2007, Reston, VA, USA. Wheelwright SM IDrugs; 2008 Feb; 11(2):94-6. PubMed ID: 18240091 [No Abstract] [Full Text] [Related]
50. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification. Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950 [TBL] [Abstract][Full Text] [Related]
51. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments. Yvon AM Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596 [No Abstract] [Full Text] [Related]
52. Possible anticompetitive agreements between brand, generic companies to be studied. Landis NT Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691 [No Abstract] [Full Text] [Related]
56. Hatch-Waxman in the Federal Courts: from 1994--2004. Ludwig SP; Kosinski KB; Harris J Drug Dev Ind Pharm; 2005 Jan; 31(2):215-22. PubMed ID: 15773288 [TBL] [Abstract][Full Text] [Related]
57. The policy outlook from the Hill. Vastag B Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381 [No Abstract] [Full Text] [Related]
58. Biotechs go generic: the same but different. Ledford H Nature; 2007 Sep; 449(7160):274-6. PubMed ID: 17882194 [No Abstract] [Full Text] [Related]
59. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. Kesselheim AS; Avorn J; Sarpatwari A JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619 [TBL] [Abstract][Full Text] [Related]